CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC)

Category Primary study
JournalJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 0129e87667963209884a52a1bc875a0c7f253dce
First added on: Feb 08, 2025